Salud financiera de hoja de balance de Claritas Pharmaceuticals

Salud financiera controles de criterios 0/6

Datos insuficientes para determinar la salud financiera de Claritas Pharmaceuticals

Información clave

n/a

Ratio deuda-patrimonio

n/a

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	n/a
Patrimonio	n/a
Total pasivo	n/a
Activos totales	n/a

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Datos insuficientes para determinar si los activos a corto plazo de CLAS.H cubren sus pasivos a corto plazo.

Pasivo a largo plazo: Datos insuficientes para determinar si los activos a corto plazo de CLAS.H cubren sus pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: Datos insuficientes para calcular el ratio deuda neta-patrimonio de CLAS.H para determinar si es satisfactorio.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de CLAS.H se ha reducido en los últimos 5 años.

Cobertura de la deuda: Datos insuficientes para determinar si la deuda de CLAS.H está bien cubierta por el flujo de caja operativo.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de CLAS.H sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de Claritas Pharmaceuticals

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Insufficient new directors

Claritas Pharmaceuticals, Inc. Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Pharmaceuticals, Inc. Announces Receipt of Comments from Australian Ethics Committee Regarding its Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas Pharmaceuticals, Inc. to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Announces Publication of Peer-Reviewed Article Reporting That R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas Pharmaceuticals, Inc. announced that it expects to receive funding from Obsidian Global Partners, LLC

Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

Claritas Pharmaceuticals, Inc. announced that it expects to receive CAD 0.18375 million in funding

Claritas Pharmaceuticals, Inc. announced that it expects to receive CAD 0.25 million in funding

Claritas Pharmaceuticals, Inc. Announces Board Changes

Independent Interim Chairman Ronald Erickson has left the company

Independent Director has left the company

Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies

Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107

Claritas (Formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea to the Board of Directors

Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed

Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections

Claritas Pharmaceuticals to Focus on Development of R-107 as A Therapy for Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera